Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis

Journal of Clinical Psychopharmacology

Volumn 24, Issue 6, 2004, Pages 613-617

  Mosyagin, Igor ^a   Dettling, Michael ^b   Roots, Ivar ^b   Mueller Oerlinghausen, Bruno ^c   Cascorbi, Ingolf ^a,d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c German Medical Association   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CARBIMAZOLE; CLOZAPINE; COTRIMOXAZOLE; CYTOKINE; CYTOKINE RECEPTOR; GENOMIC DNA; MYELOPEROXIDASE; OLANZAPINE; PERAZINE; PHENYTOIN; PIMOZIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SALAZOSULFAPYRIDINE; THIAMAZOLE; TICLOPIDINE;

3' UNTRANSLATED REGION; ADULT; AGED; AGRANULOCYTOSIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYBA GENE; DNA POLYMORPHISM; DRUG INDUCED DISEASE; ENZYME SUBUNIT; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; NADPH OXIDASE; ODDS RATIO; PEROXIDASE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 8744304914     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000144891.52858.a6     Document Type: Article

References (25)

1. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329:162-167.
2. Iqbal MM, Rahman A, Husain Z, et al. A clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33-48.
3. Schillevoort I, de Boer A, Herings RM, et al. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother. 2001;35:1517-1522.
4. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry. 1994;55(suppl B):137-138.
5. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169:483-488.
6. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry. 1994;55:44-49.
7. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther. 1997;283:1375-1382.
8. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol. 2000;58:207-216.
9. Pollmacher T, Schuld A, Kraus T, et al. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr Neurol Psychiatr. 2001;69(suppl 2):S65-S74.
10. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther. 1995;275:1476-1483.
11. Piedrafita FJ, Molander RB, Vansant G, et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412-14420.
12. Dinauer MC, Orkin SH, Brown R, et al. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature. 1987;327:717-720.
13. Inoue N, Kawashima S, Kanazawa K, et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation. 1998;97:135-137.
14. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102:1744-1747.
15. Gardemann A, Mages P, Katz N, et al. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis. 1999;145:315-323.
16. Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry. 2000;33:218-220.
17. Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics. 2001;11:135-141.
18. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001-5003.
19. Cascorbi I, Henning S, Brockmöller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res. 2000;60:644-649.
20. Wolf G, Panzer U, Harendza S, et al. No association between a genetic variant of the p22(phox) component of NAD(P)H oxidase and the incidence and progression of IgA nephropathy. Nephrol Dial Transplant. 2002;17:1509-1512.
21. van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159:369-374.
22. Sachse C, Ruschen S, Dettling M, et al. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther. 1999;66:431-438.
23. Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997;89:4167-4174.
24. Rojas M, Godschalk R, Alexandrov K, et al. Myeloperoxidase-463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis. 2001;22:1015-1018.
25. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias. What is new? J Intern Med. 2001;250:476-491.